UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2026)
UroGen Pharma's (URGN) quarterly Income from Continuing Operations came in at 23574000.0 in Q1 2026, up 46.23% YoY from 16121083.14 in Q1 2025, and down 361.93% on a QoQ basis from 9000000.0 in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Income from Continuing Operations data on file, last reported at 23574000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 46.23% year-over-year to 23574000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97861000.0 (up 8.6% YoY) and the FY2025 annual result came in at 118130000.0, down 23.68% from the prior year.
- Income from Continuing Operations fell to 23574000.0 in Q1 2026, from 9000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9000000.0 in Q4 2025 to a low of 49940000.0 in Q2 2025.
- A 5-year average of 23300352.94 and a median of 25831000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 1284.97% — and 2025, when it soared 246.34%.
- Tracing URGN's Income from Continuing Operations over 5 years: stood at 2267000.0 in 2022, then soared by 122.89% to 519000.0 in 2023, then plunged by 1284.97% to 6150000.0 in 2024, then soared by 246.34% to 9000000.0 in 2025, then slumped by 361.93% to 23574000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 23574000.0 (Q1 2026), 9000000.0 (Q4 2025), and 33347000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | -14.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.35 Mn |
| Mar 31, 2026 | -23.57 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | -33.35 Mn |
| Jun 30, 2025 | -49.94 Mn |
| Mar 31, 2025 | -43.84 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -23.67 Mn |
| Jun 30, 2024 | -33.40 Mn |
| Mar 31, 2024 | -32.29 Mn |
| Dec 31, 2023 | 519,000.00 |
| Sep 30, 2023 | -21.88 Mn |
| Jun 30, 2023 | -24.14 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -2.27 Mn |
| Sep 30, 2022 | -25.83 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -28.39 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -30.21 Mn |